PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Stock, S.* ; Kluever, A.K.* ; Endres, S. ; Kobold, S.

Enhanced chimeric antigen receptor T cell therapy through co‐application of synergistic combination partners.

Biomedicines 10:307 (2022)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable response rates and revolutionized the treatment of patients suffering from defined hematological malignancies. However, many patients still do not respond to this therapy or relapse after an initial remission, underscoring the need for improved efficacy. Insufficient in vivo activity, persistence, trafficking, and tumor infiltration of CAR T cells, as well as antigen escape and treatment‐associated adverse events, limit the therapeutic success. Multiple strategies and approaches have been investigated to further improve CAR T cell therapy. Besides genetic modification of the CAR itself, the combination with other treatment modalities has the potential to improve this approach. In particular, combining CAR T cells with clinically approved compounds such as monoclonal antibodies and small molecule inhibitors might be a promising strategy. Combination partners could already be applied during the production process to influence the cellular composition and immunophenotype of the final CAR T cell product. Alternatively, simultaneous administration of clinically approved compounds with CAR T cells would be another feasible avenue. In this review, we will discuss current strategies to combine CAR T cells with compounds to overcome recent limitations and further enhance this promising cancer therapy, potentially broadening its application beyond hematology.
Impact Factor
Scopus SNIP
Altmetric
4.757
1.444
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Adoptive T Cell Therapy ; Chimeric Antigen Receptor ; Combination Therapies; Cytokine-release Syndrome; B-cell; Antitumor-activity; Inhibitor Ibrutinib; Checkpoint Blockade; Pd-1 Blockade; Tumor Burden; Immunotherapy; Cd8(+); Improves
Sprache englisch
Veröffentlichungsjahr 2022
HGF-Berichtsjahr 2022
ISSN (print) / ISBN 2227-9059
e-ISSN 2227-9059
Zeitschrift Biomedicines
Quellenangaben Band: 10, Heft: 2, Seiten: , Artikelnummer: 307 Supplement: ,
Verlag MDPI
Verlagsort Basel, Switzerland
Begutachtungsstatus Peer reviewed
Institut(e) Unit for Clinical Pharmacology (KKG-EKLiP)
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Immune Response and Infection
PSP-Element(e) G-522100-001
Förderungen SFB-TRR 338/1 2021452881907
Hector foundation
International Doctoral Program i-Target: Immunotargeting of Cancer - Elite Network of Bavaria
Melanoma Research Alliance Grants
Else Kroener-Fresenius-Stiftung
German Cancer Aid
Ernst-Jung-Stiftung
LMU Munichs Institutional Strategy LMUexcellent within German Excellence Initiative
Bundesministerium fuer Bildung und Forschung
European Research Council
German Research Foundation (DFG)
Fritz-Bender Foundation
Jose-Carreras Foundation
Marie Sklodowska-Curie Program Training Network for Optimizing Adoptive T Cell Therapy of Cancer - H2020 Program of the European Union
DOI 10.3390/biomedicines10020307
WOS ID WOS:000764293300001
Scopus ID 85123641668
PubMed ID 35203517
Erfassungsdatum 2022-06-08
[➜Korrektur melden]